A lot of action will be droppin' in the Windy City starting in ~24 hours. In addition to Resverlogix's two presentations at AHA, there is a lot of attention on some late breaking clinical trials presenting on Saturday.

REDUCE-IT: The Primary Results of the REDUCE-IT Trial (see top-line announcement here)

DECLARE – TIMI 58: The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial (see top-line announcement here)

CIRT: The Cardiovascular Inflammation Reduction Trial (CIRT): Low Dose Methotrexate for the Prevention of Atherosclerotic Event (see trial halt announcement here)

Should be an exciting weekend for cardiovascular medicine!

BDAZ